Prosecution Insights
Last updated: October 21, 2026
Application No. 18/646,264

IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE

Non-Final OA §102§DP
Filed
Apr 25, 2024
Priority
Apr 28, 2023 — provisional 63/499,117 +1 more
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Atai Therapeutics, Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
862 granted / 1268 resolved
+8.0% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
71 currently pending
Career history
1348
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
17.6%
-22.4% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
40.3%
+0.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1268 resolved cases

Office Action

§102 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is the first action on the merits. Election/Restrictions Applicant's election without traverse of Group (I) in the reply filed on July 28, 2026 is acknowledged. Group (I), drawn to compounds of formula (I), and compositions thereof, embraced by claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39, 82 and 103 was elected by Applicant. Applicant has not pointed to any errors in the Examiner’s analysis of the classification of the different inventions. The requirement is still deemed proper and is therefore made FINAL. Applicant elected the following species: PNG media_image1.png 87 160 media_image1.png Greyscale , and indicated claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39 and 103 read on said species. Claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39, 40, 51, 52, 82, 83, 103, 105 and 106 are pending and claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39 and 103 are under consideration. Claim 82 is withdrawn based on the elected species and claims 40, 51 ,52, 82, 83, 105 and 106 are withdrawn based on the restriction requirement. Information Disclosure Statement The applicant has an obligation to call the most pertinent prior art to the attention of the U.S. Patent and Trademark Office in a proper fashion. Burying one reference in one hundred other IDS references is like citing nothing. PENN YAN BOATS, INC. v. SEA LARK BOATS, INC. 175 USPQ 260 (S.D. Fla. 1972). Golden Valley Microwave Foods, Inc. v. Weaver Popcorn Co. Inc., 24 USPQ2d 1801 (U.S. Dist. N. Dist. IN 1992). Claim Rejections Claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39 and 103 are rejected as each directed to an improper Markush group. These Markush claims are rejected under the judicially approved ‘‘improper Markush grouping’’ doctrine when the claim contains an improper grouping of alternatively useable species. In re Harnisch, 206 USPQ 300 (CCPA 1980). A Markush claim contains an ‘‘improper Markush grouping’’ if: (1) the species of the Markush group do not share a ‘‘single structural similarity,’’ or (2) the species do not share a common use. The species of the present claims do not share a ‘‘single structural similarity. Therefore, a rejection on the basis that the claims contain an ‘‘improper Markush grouping’’ is appropriate. The rejection of the claims will be maintained on the basis that the claims contain an ‘‘improper Markush grouping’’ until the claims are amended to include only species that share a single structural similarity and a common use, or the applicant presents a sufficient showing that the species in fact share a single structural similarity and a common use. Under principles of compact prosecution, the applicant elected a single disclosed species for search and examination (i.e., an election of species). The prior art search did not find the elected species in the prior art, and the search has been extended to those additional species that fall within the scope of a permissible Markush claim. In other words, the search has been extended to the species that share a single structural similarity and a common use. Proper Markush claims will be examined for patentability over the prior art with respect to the elected species or group of indistinct species, as well as the species that share a single structural similarity and a common use with the elected species or group of indistinct species (i.e., the species that would fall within the scope of a proper Markush claim). Federal Register, Vol. 76, No. 27, 02-09-2011, page 7166. Claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39 and 103, directed to the nonelected species, are withdrawn from further consideration. The prior art search will not be extended unnecessarily to cover all nonelected species. Here, the Markush group is so expansive that persons skilled in the art could not determine the metes and bounds of the claimed invention. To overcome the rejection, the claims may be limited to the elected species Markush group, wherein Z= N. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1, 8, 11, 12, 22, 26, 31, 34, 36 and 103 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kuehne et al. (J. Med. Chem., 2003, 46(13), 2716-2730). The reference teaches the following species: PNG media_image2.png 113 240 media_image2.png Greyscale , see page 2718, right-hand side, compound 36. The compound is recrystallized from diethyl ether, see page 2728, bottom right-hand column, a pharmaceutical excipient. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1, 6, 8, 11, 12, 17, 22, 26, 31, 34, 36, 39 and 103 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3, 6, 8, 11, 13, 18, 21, 22, 25, 27 and 78 of copending Application No. 18981137. Although the conflicting claims are not identical, they are not patentably distinct from each other because the present claims are drawn to a compound of formula (I), see formula below, wherein Z= N, based on the elected species. PNG media_image3.png 192 317 media_image3.png Greyscale The claims in the ‘137 application are drawn to compounds of formula (I), see below, wherein Z= N and the specific species found in claim 27, which are embraced by the present claims too. PNG media_image4.png 189 401 media_image4.png Greyscale PNG media_image5.png 319 561 media_image5.png Greyscale This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. No obviousness-type double patenting rejections over co-pending applications 19143299 and 19143810 are being made because there is no overlap based on the fused nitrogen containing [2.2.2]bicycle and the [2.2.1]bicycle. Thus, the obviousness-type double patenting was considered but not applied. The structural difference between the species of said applications means that the two are patentably distinct. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray, can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Apr 25, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §102, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767658
TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF
4y 6m to grant Granted Oct 20, 2026
Patent 12760059
GLUCOCORTICOID RECEPTOR MODULATORS
3y 11m to grant Granted Oct 13, 2026
Patent 12753202
ANDROGEN RECEPTOR MODULATORS
4y 0m to grant Granted Oct 06, 2026
Patent 12735434
FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
3y 4m to grant Granted Sep 15, 2026
Patent 12723043
METHOD FOR PREPARING MORPHINAN DERIVATIVE HAVING DIARYL ETHER SKELETON USING NOVEL COPPER CATALYST
3y 6m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+31.6%)
2y 11m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1268 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month